JAK3-STAT pathway blocking benefits in experimental lupus nephritis
Authors:
Open Access
- 8 June 2016
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-12
Abstract
Lupus nephritis (LN) is a complex chronic autoimmune disease of unknown etiology characterized by loss of tolerance against several self-antigens. Cytokines are known to be central players in LN pathogenesis. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is one important pathway that mediates signal transduction of several cytokines. In this study, we examined the pathogenic role of this pathway and how CP-690,550 treatment influences LN outcome. Six-month-old NZB/NZWF1 mice were divided into two different treatment groups: (1) control animals given vehicle treatment, cyclophosphamide, and mycophenolate mofetil treatment as positive controls of the therapy and (2) mice treated with CP-690,550, a JAK3 inhibitor. Mice were treated for 12 weeks. We evaluated renal function, anti-double-stranded DNA (anti-dsDNA) antibody, renal histology changes, kidney complement and immunoglobulin G (IgG) deposits, T-cell and macrophage infiltration, kidney inflammatory gene expression, and circulating cytokine changes. CP-690,550 treatment significantly reduced proteinuria and improved renal function and histological lesions of the kidney. Compared with vehicle-treated animals, those undergoing CP-690,550 treatment showed significantly diminished anti-dsDNA antibody and complement component C3 and IgG deposition in glomeruli. We also observed a significant reduction of T-cell and macrophage infiltration. Kidney gene expression revealed a reduction in inflammatory cytokines and complement and related macrophage-attracting genes. Circulating inflammatory cytokines were also reduced with treatment. On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the course of experimental LN. Thus, CP-690,550 could become a new therapeutic tool in LN and other autoimmune diseases.Keywords
Funding Information
- Instituto de Salud Carlos III (Sara Borrell, PI14/00762)
- Amgen Foundation
- Fundació la Marató de TV3 (144/U/2012)
- Societat Catalana de Trasplantament
This publication has 38 references indexed in Scilit:
- Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosusLupus, 2013
- CD40 Gene Silencing Reduces the Progression of Experimental Lupus Nephritis Modulating Local Milieu and Systemic MechanismsPLOS ONE, 2013
- Interleukin-17 Expression Positively Correlates with Disease Severity of Lupus Nephritis by Increasing Anti-Double-Stranded DNA Antibody Production in a Lupus Model Induced by Activated Lymphocyte Derived DNAPLOS ONE, 2013
- Mechanisms of tissue injury in lupus nephritisArthritis Research & Therapy, 2011
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)The Journal of Immunology, 2011
- Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal modelsArthritis Research & Therapy, 2011
- The Role of Cytokine in the Lupus NephritisBioMed Research International, 2011
- CD40 and autoimmunity: The dark side of a great activatorSeminars in Immunology, 2009
- Pathogenesis of kidney disease in systemic lupus erythematosusCurrent Opinion in Rheumatology, 2009
- Autoimmune diseases: insights from genome-wide association studiesHuman Molecular Genetics, 2008